Global minimal residual disease (MRD) testing market will reach $ 2,858.1 million by 2031, growing by 12.4% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure. Get Sample Report ......